Historical Background
Protein kinase C was discovered in the late 1970s by Yasutomi Nishizuka and his team at Kobe University, Japan. They had originally purified a kinase that required only Mg2+ for activity, so they named it protein kinase M (PKM). It soon became apparent to the group that PKM was a proteolytic product of a larger enzyme whose kinase activity needed to be unmasked by cofactors. They named the parent enzyme protein kinase C because a Ca2+-dependent protease cleaved it to release the unregulated kinase moiety they had initially purified. The subsequent identification of diacylglycerol as the key cofactor provided an explanation for how lipid hydrolysis, discovered 25 years earlier to be triggered by stimuli such as acetylcholine, couples to intracellular signaling pathways. But the discovery that shot PKC into the limelight was its specific binding to, and activation by, tumor-promoting phorbol esters, a discovery that was facilitated by the synthesis of relatively...
References
Alfonso SI, Callender JA, Hooli B, Antal CE, Mullin K, Sherman MA, Lesne SE, Leitges M, Newton AC, Tanzi RE, et al. Gain-of-function mutations in protein kinase Calpha (PKCalpha) may promote synaptic defects in Alzheimer’s disease. Sci Signal. 2016;9:ra 47.
Antal CE, Callender JA, Kornov AP, Taylor SS, Newton AC. Intramolecular C2 domain-mediated autoinhibition of protein kinase CbII. Cell Rep. 2015a. doi:10.1016/j.celrep.2015.07.039.
Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, et al. Cancer-associated protein kinase C mutations reveal kinase’s role as tumor suppressor. Cell. 2015b;160:489–502.
Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008;27:1932–43.
Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem. 2008;283:6300–11.
Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Natl Rev Cancer. 2007;7:281–94.
Hansra G, Garcia-Paramio P, Prevostel C, Whelan RD, Bornancin F, Parker PJ. Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes [In Process Citation]. Biochem J. 1999;342:337–44.
Hein MY, Hubner NC, Poser I, Cox J, Nagaraj N, Toyoda Y, Gak IA, Weisswange I, Mansfeld J, Buchholz F, et al. A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Cell. 2015;163:712–23.
Hoshi N, Langeberg LK, Gould CM, Newton AC, Scott JD. Interaction with AKAP79 modifies the cellular pharmacology of PKC. Mol Cell. 2010;37:541–50.
Humphries MJ, Ohm AM, Schaack J, Adwan TS, Reyland ME. Tyrosine phosphorylation regulates nuclear translocation of PKCdelta. Oncogene. 2008;27:3045–53.
Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008;27:1919–31.
Leonard TA, Rozycki B, Saidi LF, Hummer G, Hurley JH. Crystal structure and allosteric activation of protein kinase C betaII. Cell. 2011;144:55–66.
Newton AC. Diacylglycerol’s affair with protein kinase C turns 25. Trends Pharmacol Sci. 2004;25:175–7.
Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607–14.
Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Natl Rev Mol Cell Biol. 2010;11:103–12.
Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J. 2004;384:449–59.
Stempka L, Girod A, Müller H-J, Rincke G, Marks F, Gschwendt M, Bossemeyer D. Phosphorylation of protein kinase Cd (PKCd) at threonine 505 is not a prerequisite for enzymatic activity. J Biol Chem. 1997;272:6805–11.
Tobias IS, Kaulich M, Kim PK, Simon N, Jacinto E, Dowdy SF, King CC, Newton AC. Protein kinase Czeta exhibits constitutive phosphorylation and phosphatidylinositol-3,4,5-triphosphate-independent regulation. Biochem J. 2016;473:509–23.
Tobias IS, Newton AC. Protein scaffolds control localized protein kinase C zeta activity. J Biol Chem. 2016;291:13809–22.
Trujillo JI, Kiefer JR, Huang W, Thorarensen A, Xing L, Caspers NL, Day JE, Mathis KJ, Kretzmer KK, Reitz BA, et al. 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem Lett. 2009;19:908–11.
Verbeek DS, Goedhart J, Bruinsma L, Sinke RJ, Reits EA. PKC gamma mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. J Cell Sci. 2008;121:2339–49.
Violin JD, Zhang J, Tsien RY, Newton AC. A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C. J Cell Biol. 2003;161:899–909.
Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell. 2015;163:1237–51.
Wu-Zhang AX, Newton AC. Protein kinase C pharmacology: refining the toolbox. Biochem J. 2013;452:195–209.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media LLC
About this entry
Cite this entry
Newton, A.C. (2016). Protein Kinase C (Prkc). In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6438-9_101822-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6438-9_101822-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-6438-9
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences